Key Points
- Beta Bionics CFO Stephen Feider sold 4,896 shares on June 29 at an average price of $17.03, totaling about $83,379. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Feider has also sold shares in two recent transactions, including 5,104 shares on June 26 and 6,676 shares on June 2, indicating a pattern of insider selling over the past month.
- BBNX shares were down 7.8% and opened at $15.67, while analysts currently have a Moderate Buy consensus with an average price target of $19.70.
Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) CFO Stephen Feider sold 4,896 shares of Beta Bionics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.03, for a total transaction of $83,378.88. Following the transaction, the chief financial officer directly owned 165,931 shares in the company, valued at approximately $2,825,804.93. This represents a 2.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stephen Feider also recently made the following trade(s):
- On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The stock was sold at an average price of $17.05, for a total value of $87,023.20.
- On Tuesday, June 2nd, Stephen Feider sold 6,676 shares of Beta Bionics stock. The shares were sold at an average price of $12.61, for a total value of $84,184.36.
Beta Bionics Stock Down 7.8%
BBNX stock opened at $15.67 on Wednesday. Beta Bionics, Inc. has a 12-month low of $8.80 and a 12-month high of $32.71. The firm has a market cap of $698.26 million, a PE ratio of -10.38 and a beta of 3.40. The business has a 50 day moving average of $12.28 and a 200-day moving average of $15.31.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The company had revenue of $27.63 million during the quarter. On average, research analysts expect that Beta Bionics, Inc. will post -2.22 earnings per share for the current year.
Hedge Funds Weigh In On Beta Bionics
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock valued at $44,036,000 after purchasing an additional 1,509,217 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Beta Bionics during the fourth quarter valued at about $40,437,000. Eversept Partners LP boosted its position in Beta Bionics by 108.6% during the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company's stock valued at $14,177,000 after buying an additional 736,576 shares during the period. 12 West Capital Management LP purchased a new stake in Beta Bionics during the fourth quarter valued at about $17,520,000. Finally, Bruce & Co. Inc. bought a new position in shares of Beta Bionics during the first quarter valued at about $5,518,000.
Analyst Ratings Changes
BBNX has been the topic of a number of recent research reports. Weiss Ratings cut Beta Bionics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, April 21st. The Goldman Sachs Group lowered their price target on shares of Beta Bionics from $19.00 to $17.00 and set a "buy" rating on the stock in a research report on Wednesday, May 27th. Stifel Nicolaus cut their price objective on shares of Beta Bionics from $22.00 to $20.00 and set a "buy" rating for the company in a report on Wednesday, April 22nd. Leerink Partners dropped their price objective on Beta Bionics from $25.00 to $24.00 and set an "outperform" rating on the stock in a report on Wednesday, April 22nd. Finally, Wall Street Zen cut Beta Bionics from a "hold" rating to a "sell" rating in a research report on Sunday, March 29th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $19.70.
Check Out Our Latest Research Report on BBNX
About Beta Bionics
(
Get Free Report)
Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.
At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
